Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.

MLA

Hutchins, Laura F., et al. “Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil versus Cyclophosphamide, Doxorubicin, and Fluorouracil with and without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 23, no. 33, Nov. 2005, pp. 8313–21. EBSCOhost, https://doi.org/10.1200/JCO.2005.08.071.

APA

Hutchins, L. F., Green, S. J., Ravdin, P. M., Lew, D., Martino, S., Abeloff, M., Lyss, A. P., Allred, C., Rivkin, S. E., & Osborne, C. K. (2005). Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 23(33), 8313–8321. https://doi.org/10.1200/JCO.2005.08.071

Chicago

Hutchins, Laura F, Stephanie J Green, Peter M Ravdin, Danika Lew, Silvana Martino, Martin Abeloff, Alan P Lyss, Craig Allred, Saul E Rivkin, and C Kent Osborne. 2005. “Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil versus Cyclophosphamide, Doxorubicin, and Fluorouracil with and without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23 (33): 8313–21. doi:10.1200/JCO.2005.08.071.